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Hepatitis delta virus (HDV) is a defective RNA virus which is dependent on hepatitis B virus for essential
helper functions. Only a single highly basic phosphoprotein, HDV antigen (HDAg), is expressed by the HDV
genome during infection in humans. Antibody directed to HDAg is important in the diagnosis ofHDV infection,
and it is likely but not yet proven that the immune response to HDAg provides significant protection against
subsequent exposures to HDV. In an effort to map the antigenic domains of HDAg, 209 overlapping
hexapeptides, spanning the entire 214 amino acid residues of the protein, were synthesized on polyethylene pins
and probed by enzyme-linked immunosorbent assay with sera containing high titers of anti-HD antibodies.
Domains recognized by antibodies present in serum from human chronic carriers of this virus included residues
2 to 7, 63 to 74, 86 to 91, 94 to 100, 159 to 172, 174 to 195, and 197 to 207. Antibody from an acutely
superinfected woodchuck recognized similar epitopes, as well as a domain spanning residues 121 to 128.
Together, residues in these antigenic domains constitute 41% of the HDAg molecule. Oligopeptides 15 to 29
residues in length and representing epitopes of HDAg found to be dominant in humans (residues 2 to 17, 156
to 184, and 197 to 211) were synthesized in bulk and found to possess significant antigenic activity by
microdilution enzyme-linked immunosorbent assay. The reactivity of peptide 197-211 with human sera
confirms that the entire 214 amino acids of HDAg are expressed during infection in vivo. In addition, these
results suggest that synthetic peptides may be useful reagents for development of new and improved diagnostic
tests for HDV infection.
Hepatitis delta virus (HDV) is a unique human pathogen
which has been implicated, in association with hepatitis B
virus (HBV), as a cause of severe acute hepatitis and
progressive chronic liver disease (7). The HDV virion con-
sists of a circular, single-stranded RNA genome approxi-
mately 1.7 kilobases in length (17, 19, 26, 27) and a highly
basic phosphoprotein (hepatitis delta antigen [HDAg]) (4, 5)
packaged within an envelope composed of hepatitis B sur-
face antigen (HBsAg) (3, 24). HBsAg present in the HDV
virion is encoded by HBV DNA, and current data indicate
the HBV coinfection is an absolute prerequisite for signifi-
cant infection and disease associated with HDV in humans.
Complete genomic sequences have been independently
derived from cDNA clones established from two different
HDV strains, one after chimpanzee passage (26, 27) and the
other directly from human serum (19). Analysis of these
sequences has shown that virion RNA contains two open
reading frames (ORF) capable of encoding proteins of longer
than 100 amino acids, while the antigenomic sequence
contains three additional open reading frames of equivalent
length (19, 26, 27). Thus, the HDV genome potentially
encodes up to five different proteins of significant length.
HDAg has been shown to be encoded by one of the open
reading frames in antigenomic sense RNA (5, 28): ORF-5 by
the nomenclature of Wang et al. (26, 27), or ORF-2 by
Makino et al. (19). Thus, HDV is a negative-stranded RNA
virus. HDAg is present in HDV particles in two distinct
forms having molecular weights of 27,000 (p278) and 24,000
(p248) (3, 28). Present knowledge of the differences between
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these two HDAg species is incomplete. ORF-5 potentially
encodes a protein 214 amino acids in length, thought to
represent p278 (19, 26, 27). It has been suggested that the
p248 form of HDAg may represent expression of a C-
terminal truncated protein of 195 amino acids, due to hetero-
geneity in the HDV genome reflected by the presence of an
amber stop codon in some cloned cDNAs (28). Alterna-
tively, the two molecular species may reflect posttransla-
tional processing of the primary ORF-5 expression product.
HDAg is phosphorylated at multiple serine residues and has
been shown to have RNA-binding activity of uncertain
specificity (5). Thus far, it is the only protein product clearly
recognized to be expressed by the HDV genome during in
vivo infection. Further understanding of the structure and
function of this viral protein is central to unraveling the
molecular events involved in HDV replication and the
pathogenesis of delta hepatitis.
In this report, we describe the mapping of immunogenic
domains of the HDAg molecule and the identification of
epitopes recognized by human and woodchuck antibodies to
HDAg (anti-HD). These studies utilized pin-based oligopep-
tide synthesis as an approach to the fine-structure mapping
of sequential epitopes (11). We compare the results of this
method with computer algorithms for prediction of protein
secondary structure and immunogenic domains.
MATERIALS AND METHODS
Human sera. Sera were collected from hemophiliac pa-
tients who were chronic carriers of HBV (HBsAg positive)
and enrolled in a longitudinal study exploring the contribu-
tion ofHDV infection to chronic liver disease in hemophilia.
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Control sera were obtained from two healthy individuals of
comparable age and sex, one of whom was an anti-HD-
negative, chronic HBsAg carrier. Additional sera were col-
lected from a woodchuck (Marmota monax), WC862, which
was positive for woodchuck hepatitis virus and experimen-
tally superinfected with human HDV in collaboration with
John Cullen of the School of Veterinary Medicine, North
Carolina State University. Woodchuck hepatitis virus is a
hepadnavirus that is closely related to HBV and capable of
supplying helper functions necessary for the replication of
HDV (22). The anti-HD activity of these sera was deter-
mined by a commercially available competitive enzyme-
linked immunosorbent assay (ELISA) (Delta EIA; Abbott
Laboratories, North Chicago, Ill.). HBsAg was also de-
tected in sera by a commercial ELISA (Auszyme; Abbott
Laboratories).
Anti-HD radioimmunoassay. Additional testing for anti-
HD was carried out by a microdilution solid-phase compet-
itive radioimmunoassay modified from that described by
Rizzetto et al. (25). HDAg used in this assay was extracted
from the liver of an acutely superinfected, woodchuck
hepatitis virus-positive woodchuck (WC643) by preparing
tissue homogenates in 6 M guanidine hydrochloride (pH 6.0),
followed by dialysis against phosphate-buffered saline
(PBS), as described by Bergmann and Gerin (1). Flexible
polyvinyl chloride microdilution plate wells were coated for
2 h at 35°C with 100 ,ul of a human anti-HD-positive serum
(AI035) diluted 1:4,000 in 50 mM carbonate buffer (pH 9.6),
washed with PBS containing 0.5% Tween 20 (PBS-T), and
loaded with 40 ,ul of the HDAg preparation. After 2 h of
incubation at 37°C, the plates were washed with PBS-T, and
50 ,lI of a 1:100 dilution of test serum in PBS was added to
each well. Following an overnight incubation at 4°C, wells
were washed with PBS-T and incubated for 4 h at 4°C with 50
pA of 125I-labeled immunoglobulin G (IgG; 50,000 cpm),
isolated from the serum of an anti-HD-positive hemophiliac
patient (ET87) by chromatography through DEAE-Sepha-
cryl (Pharmacia, Piscataway, N.J.), iodinated by the chlo-
ramine-T method, and diluted in 10% fetal calf serum.
Immunoblot detection of anti-HD. Immunoblots were car-
ried out with HDAg prepared from woodchuck serum, as
this source provides antigen of less complexity than that
present in liver (1). Serum (1.0 ml) taken from an acutely
superinfected woodchuck (WC643) was layered over an
11-ml cushion containing 20% sucrose in 0.02 M HEPES
(N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) (pH
7.4)-0.01 M CaCl2-0.01 M MgCl2-0.1% bovine serum albu-
min and centrifuged for 5 h at 150,000 x g in an SW40 rotor
(Beckman Instruments, Inc., Palo Alto, Calif.). Pelleted
HDAg was suspended in distilled water and stored at -70°C
until use. Antigen diluted in sample buffer (0.0625 M Tris
[pH 6.8], 1% sodium dodecyl sulfate, 1% 2-mercapto-etha-
nol, 10% glycerol, 0.002% bromophenol blue) was separated
by sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis with stacking and separating gels containing 4 and 12.5%
polyacrylamide, respectively. Separated polypeptides were
electrophoretically transferred to nitrocellulose paper at 85
mA for 3 h at 4°C. Nitrocellulose papers were blocked with
blocking buffer (3% milk, 50 mM Tris, 150 mM sodium
chloride, 5 mM EDTA, 0.25% gelatin, 0.05% sodium azide
[pH 7.4]) for 30 min and incubated with test serum diluted
1:1,000 in blocking buffer for 1 h at room temperature. After
washing in PBS-T, nitrocellulose papers were incubated for
30 min with horseradish peroxidase-conjugated goat anti-
human IgG (Bethesda Research Laboratories, Inc., Gaith-
ersburg, Md.) diluted in PBS. Following an additional wash-
ing step, the papers were placed in freshly prepared
substrate solution (25 mg of 3,3-diaminobenzidine in 50 ml of
0.05 M Tris, 0.02% hydrogen peroxide [pH 7.4]) for color
development.
Pin-based oligopeptide synthesis. Overlapping hexapep-
tides spanning the entire HDAg molecule were synthesized
on polyethylene pins with materials provided as components
of the Epitope Mapping Kit manufactured by Cambridge
Research Biochemicals, Inc., Valley Stream, N.Y. This
method of peptide synthesis uses preformed active ester
coupling with 9-fluoroenylmethyl-oxycarbonyl and t-butyl-
oxycarbonyl protection. Its application to epitope mapping
has been extensively described by Geysen et al. (11-13).
Pin-based oligopeptide ELISA. Oligopeptide-bearing pins,
disrupted by sonication as described below, were blocked by
incubation for 1 h at room temperature in microdilution
plates containing 200 ,ul of blocking buffer per well. Pins
were then transferred to a microdilution plate containing, per
well, 175 ,ul of test serum diluted 1:6,000 or more in blocking
buffer. Following incubation at 4°C for 24 to 48 h, pins were
subjected to three cycles of washing in PBS-T, 30 min per
cycle with agitation, and transferred to wells containing
horseradish peroxidase-conjugated goat anti-human IgG di-
luted in blocking buffer without sodium azide. Woodchuck
antibody was detected by sequential incubations with rabbit
antiserum raised to woodchuck immunoglobulin and horse-
radish peroxidase-conjugated goat anti-rabbit IgG. After
being washed as above, pins were placed in microdilution
wells containing'150 ,ul of freshly prepared substrate solution
{25 mg of 2,2'-azino-di-[3-ethylbenzthiazoline sulfonate (6)]
(Boehringer-Mannheim Biochemicals, Indianapolis, Ind.) in
50 ml of 0.1 M disodium hydrogen phosphate, 0.08 M citric
acid, 0.015% hydrogen peroxide, pH 4.0} and held at room
temperature in the dark for 30 min. Color development was
stopped by removing the pins, and the A405 of the substrate
solutions was determined immediately by reading in an
automated ELISA plate reader. Data were downloaded to an
IBM-XT computer and analyzed, using Lotus 1-2-3 soft-
ware. Reactions with human sera were considered positive
when absorbance was .0.2, while woodchuck serum reac-
tions were considered positive when absorbance was .0.5.
Pins were stripped of immunoglobulin by sonication for 30
min in 1% sodium dodecyl sulfate-0.1% 2-mercaptoethanol-
0.1 M sodium dihydrogen orthophosphate at 60°C, washed
with hot (60°C) distilled water followed by boiling methanol
for 2 min, and air dried.
Bulk synthesis of oligopeptides. Peptide synthesis was
carried out with a model 9500 peptide synthesizer (Bio-
search, Novato, Calif.), in the Synthetic Peptide Facility of
the Department of Microbiology and Immunology, Univer-
sity of North Carolina-Chapel Hill, under the direction of
David Klapper. t-Butyloxycarbonyl chemistry was used for
peptide synthesis (21).
Oligopeptide ELISA for anti-HD. Oligopeptides (750 ng in
75 ,ul of carbonate buffer) were applied to the wells of
flat-bottomed ELISA plates (Falcon; Becton Dickinson Lab-
ware, Oknard, Calif.) by incubation for 2 h at 35°C in a
humidified chamber. Plates were washed with PBS-T and
blocked by the addition of 75 ,ul of blocking buffer. Serum
specimens diluted in blocking buffer (50 [lI per well) were
added to the plates, which were then incubated overnight at
4°C. Following washing with PBS-T, 50 ,ll of horseradish
peroxidase-conjugated goat anti-human IgG diluted in block-
ing buffer without sodium azide was added for 50 min at
37°C. Plates were washed with PBS, followed by the addi-
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tion of o-phenylenediamine substrate solution (55 ,ul per
well) at room temperature for 15 min in the dark. Color
development was stopped by the addition of 160 RI; of 1 N
H2SO4, and the A490 was determined by reading in an
automated ELISA plate reader.
HDAg secondary-structure predictions. Hydrophilic do-
mains of HDAg were predicted by the method of Hopp and
Woods (14), while hydrophobic regions were independently
predicted by a program which determined the mean hydro-
phobicity score for 11 residue windows, using hydrophobic
indices derived for individual side chains by Fauchere and
Pliska (9). More detailed predictions of the secondary struc-
ture of HDAg were done by means of the PEPTIDESTRUC-
TURE and PLOTSTRUCTURE programs of the University
of Wisconsin Genetics Computer Group Sequence Analysis
Software Package (15). These programs include predictions
of hydrophilicity by the method of Kyte and Doolittle (18),
peptide secondary structure by Chou and Fasman (6) and
Garnier et al. (10), and surface probability by Emini et al. (8).
From these predictive measures, an antigenic index is de-
rived by the algorithm developed by Jameson and Wolf (15).
The antigenic index is a measure of the probability that a
domain is antigenic and is calculated by summing weighted
values for surface accessibility, regional backbone flexi-
bility, and certain features of predicted secondary structure.
For comparison with hexapeptide ELISA results and subse-
quent statistical analysis, the following criteria were used:
hydrophilicity, .1.3; surface probability, -5; flexibility,
>1.04; antigenic index, -1.2; and "turn" or "strong turn"
in secondary-structure predictions. In addition, regions pre-
dicted to be amphipathic alpha-helices (putative T-cell de-
terminants) were identified by a program developed by
Margalit et al. (20).
RESULTS
HDAg epitope mapping with overlapping hexapeptides. We
synthesized 209 overlapping hexapeptides spanning the 214
amino acids of human HDAg (ORF-2 expression product)
predicted from the nucleotide sequence of cloned HDV
cDNA reported by Makino et al. (19). Hexapeptides were
synthesized on polyethylene pins, using a synthesis system
supplied by Cambridge Research Biochemicals. Control
peptides (4-mers) included in the synthesis reacted specifi-
cally with murine monoclonal antibody supplied by the
manufacturer in subsequent pin-based ELISA (mean signal-
to-noise ratio, 4), confirming the validity of the synthesis.
However, preliminary pin-based ELISAs demonstrated sub-
stantial nonspecific binding of human IgG to pins supporting
HDAg hexapeptides at test serum dilutions below 1:2,000.
To overcome this problem, we determined the endpoint titer
of each of a panel of 27 anti-HD-positive sera in a competi-
tive radioimmunoassay which used as antigen HDAg ex-
tracted from woodchuck liver. These sera had been collected
from hemophiliac patients who were chronic carriers of
HBsAg. We selected for further study five serum samples
with particularly high titers of anti-HD, ranging from 1:
12,500 to .1:312,500 (Table 1). These titers of anti-HD are
highly suggestive of chronic infection with HDV. Each of
these five serum samples was strongly positive in immuno-
blot assays against denatured HDAg concentrated from
woodchuck serum, reacting with both p24' and p278 (Fig. 1).
We thus considered it likely that these sera had high-titer
antibody against sequential epitopes of HDAg that would be
detectable in hexapeptide ELISAs. Each serum was tested
at a dilution of 1:6,000 to 1:8,000 against the array of HDAg
hexapeptides.
TABLE 1. Anti-HD-positive and control human sera
Age Anti-HD ~~~~~~ScreeningSerum of donor HBsAg dilution dilutininsample (yr)a (titer)b hexapeptide
ELISA
AD062 28 + 1:62,500 (10-4) 1:6,000
AF043 24 + 1:12,500 (10-s) 1:8,000
AC036 31 + 1:62,500 (10-4) 1:8,000
AC039 20 + 21:312,500 (10-4) 1:8,000
AD099 15 + 1:62,500 (10-3) 1:7,000
A008 33 - <1:100 (<10-0) 1:8,000
A073 + <1:100 (<10-0) 1:8,000
a All serum samples were from males.
b Highest dilution yielding 50%o inhibition in competitive inhibition radio-
immunoassay with woodchuck liver-derived HDAg (comparative endpoint
titer in commercial ELISA).
Results of pin-based hexapeptide ELISAs with one serum
specimen (AC036) are shown in Fig. 2. Antibodies present in
this serum demonstrated binding activity against hexapep-
tides representing at least six discrete regions in the linear
sequence of the HDAg protein. Epitopes recognized by
binding of antibody to hexapeptides spanned residues 2 to 7,
63 to 69, 159 to 165, 167 to 172, 174 to 181, and 201 to 207.
Additional hexapeptides demonstrating low-level binding
(above background, but less than the arbitrary cut off of
absorbance of .0.2) represented residues 85 to 91 and 152 to
157 (Fig. 2). These hexapeptides may represent minor deter-
minants. Hexapeptide ELISA results with this positive
serum were highly reproducible, while two anti-HD-negative
serum samples (A008 and A073, Table 1) yielded consis-
tently negative results (mean absorbance, 0.113 and 0.121;
maximum absorbance, 0.176 and 0.157, respectively) when
tested against the hexapeptide-bearing pins at similar dilu-
tions (results not shown). Results of assays with alternating
positive and negative sera demonstrated that the stripping
procedure was effective in completely removing IgG bound
1 2 3 4 5 6 7
p27l
p24 low
FIG. 1. Immunoblot of woodchuck serum-derived HDAg with
human sera utilized in HDAg hexapeptide ELISAs. Lanes 1 to 5
were probed with anti-HD-positive sera (1) AD062, (2) AF043, (3)
AC036, (4) AC039, and (5) AD099, while lanes 6 and 7 were probed
with control sera A008 and A073, respectively.
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FIG. 2. Hexapeptide ELISA scan of HDAg with serum AC036 at a 1:8,000 dilution. Hexapeptides on pins were considered reactive with
antibody when absorbance was .0.200.
to the pins. In the course of these studies, the hexapeptide-
bearing pins were reused through 26 repetitive ELISA cycles
without noticeable loss of activity.
Subsequent screening of HDAg hexapeptides with four
other high-titer anti-HD-positive human sera identified iden-
tical or closely positioned epitopes within the protein, as
well as two additional antigenic domains. Antigenic domains
of HDAg were defined as regions containing overlapping or
contiguous hexapeptides found to be antigenic in screening
with any of the five human anti-HD-positive serum samples
A.
B.
S R G A P G G G F V P S M Q
(Fig. 3). Altogether, these domains included regions spanned
by residues 2 to 7, 63 to 74, 86 to 91, 94 to 100, 159 to 172,
174 to 195, and 197 to 207 (Table 2). Although the carboxy-
terminal 50 residues of the HDAg protein (residues 159 to
207) appeared immunodominant with each of the human sera
tested in these assays, significant variation was evident
between individual sera with respect to the degree to which
certain hexapeptides were bound by antibody (Fig. 4). These
results demonstrate the power of this approach to the
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FIG. 3. Examples of two antigenic domains of HDAg determined by pin-based hexapeptide ELISAs. Antigenic domains were defined by
overlapping or contiguous peptide sequences found to be reactive as hexapeptides when tested against any anti-HD-positive serum. Only
reactive hexapeptides are shown. When the hexapeptide was reactive with more than one of the tested sera, the values shown represent the
mean absorbance: (A) antigenic domain at residues 159 to 172; (B) antigenic domain at residues 174 to 195. See also Table 2.
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TABLE 2. Antigenic domains of HDAg defined by overlapping
hexapeptides with antigenic activitya
Serum No. of hexapeptides within given antigenic domain of HDAg
sample 1-7 63-74 86-92 94-100 121-128b 159-172 174-195 197-207
AD062 2 2 3 2
AF043 2
AC036 1 2 3 3 2
AC039 3 2 1 2 5 3
AD099 5
WC862 2 4 2 3
A008
A073
a Antigenic domains were defined by overlapping hexapeptides with anti-
genic activity determined by screening against the panel of human sera (Fig.
3). Shown are the number of hexapeptides within each domain that were
determined to have antigenic activity with each individual serum specimen
(absorbance, .0.2 for human sera or .0.5 for woodchuck serum).
b Recognized only by woodchuck serum.
the five anti-HD serum samples tested, AD099 demonstrated
relatively low-level binding of antibodies to HDAg hexapep-
tides (maximum absorbance, 0.398, compared with 0.858 to
2.272 obtained with the other four serum samples). These
results suggest that the sequential epitopes recognized by
AD099 antibodies in HDAg immunoblots (Fig. 1, lane 5) may
be poorly mimicked by synthetic peptides as short as six
residues in length.
Mapping of HDAg epitopes recognized by the woodchuck.
Hexapeptide ELISAs were carried out with serum from a
woodchuck hepatitis virus carrier woodchuck (WC862)
which was acutely superinfected with HDV. Serum was
collected following HDAg clearance from serum and the
II
0
appearance of anti-HD. The second antibody used in these
hexapeptide ELISAs, rabbit anti-woodchuck immunoglobu-
lin, generated higher background activity and required a
different standard for positivity (absorbance, .0.5). The
results of these tests (Fig. 5) indicated that the epitopes
bound by woodchuck antibodies (residues 1 to 7, 63 to 71,
121 to 128, and 197 to 204) overlap with at least some of the
antigenic domains recognized by humans (residues 2 to 7, 63
to 74, and 197 to 207). However, in contrast to the apparent
immunodominance of the carboxy-terminal region of HDAg
in humans, HDAg domains defined by hexapeptides span-
ning residues 1 to 7 and 63 to 71 were dominant in this one
woodchuck. In addition, woodchuck antibodies bound also
to hexapeptides spanning residues 121 to 128, a region not
recognized by any of the human sera tested (Table 2). These
results suggest significant interspecies differences in the
recognition of HDAg epitopes, although additional sera will
need to be tested to completely define these differences.
Comparison of hexapeptide ELISA with computer algo-
rithm predictions. We analyzed the predicted amino acid
sequence of HDAg for regions of relative hydrophilicity and
hydrophobicity, using the method of Hopp and Woods (14),
and values of relative hydrophobicity developed for individ-
ual amino acid side chains by Fauchere and Pliska (9).
Although these two methods yield somewhat different pre-
dictions of the hydrophilic and hydrophobic domains of the
protein, both suggest that the carboxy-terminal region (res-
idues 145 to 214) of HDAg is less hydrophilic than the
amino-terminal 144 residues (not shown). Neither analysis
would have predicted antigenic domains occurring within
residues 159 to 207 that appear dominant in hexapeptide
ELISAs with human sera.
Similarly, secondary-structure predictions had little suc-
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FIG. 4. Pin-based hexapeptide ELISA with hexapeptides spanning residues 151 to 214 of HDAg (carboxy-terminal 64 residues). A008 is
a control serum, while the other four serum samples contain high titers of anti-HD (Table 1).
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FIG. 5. Hexapeptide ELISA scan of HDAg with woodchuck serum WC862. Pins were considered positive when the absorbance was
.:0.500.
ary structure ofHDAg made by the PEPITIDESTRUCTURE
program (15) are shown in Fig. 6. For each hexapeptide, we
cross-classified observed antigenic activity against predic-
tions of hydrophilicity (seven-residue window), surface
probability, flexibility, secondary structure, and antigenic
index (15) generated by PEPTIDESTRUCTURE. Sensitiv-
ity, specificity, and positive and negative predictive values
(maximum 51 and 70%, respectively) were calculated for
each prediction rule (not shown). None of the methods were
good predictors. Regardless of the prediction method, the
kappa statistic, which measures chance-adjusted agreement,
never exceeded 0.21, indicating poor agreement between
predicted and observed antigenicity. Nonetheless, each of
the antigenic domains shown in Table 2 contains or is
immediately adjacent to turns in the HDAg structure pre-
dicted by the Chou-Fasman (6) or Garnier-Osguthorpe-
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FIG. 6. Analysis of the predicted HDAg (19) secondary structure by the PEPTIDESTRUCTURE program (15). Shown is the
PLOTSTRUCTURE program output detailing hydrophilicity (Kyte-Doolittle), surface probability (Emini), chain flexibility (Karplus-Schulz),
antigenic index (Jameson-Wolf), and secondary structure by the methods of Chou-Fasman (CF) and Garnier-Osguthorpe-Robson (GOR).
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FIG. 7. Oligopeptide ELISA for anti-HD. An anti-HD-positive
serum (AC036) and a negative serum (A008) were each tested at a
dilution of 1:1,000 against decreasing quantities of synthetic oli-
gopeptides applied to the wells of microdilution ELISA plates. (A)
Peptide 2-17; (B) peptide 156-184; (C) peptide 167-184; (D) peptide
197-212.
Robson (10) method (Fig. 6). Notably, of a total of 17 proline
residues within the HDAg protein, 13 occur within or
immediately adjacent to hexapeptides reactive in ELISA.
The possible influence of proline residues in two of the
antigenic domains is evident in Fig. 3. In both instances in
which there are two adjacent proline residues within the
protein (residues 69 to 70 and 204 to 205), there was evidence
of antigenic activity. Finally, although regions predicted to
be amphipathic alpha-helices are generally considered pre-
dictive of T-cell and not B-cell determinants (20), it was of
interest that five of nine predicted amphipathic segments
(residues 117 to 120, 131 to 133, 150 to 159, 170 to 177, and
179 to 183) were adjacent to or overlapped with antigenic
sites determined in hexapeptide ELISAs.
Microdilution oligopeptide ELISA for anti-HD. Based on
the results of hexapeptide ELISAs with human sera, four
oligopeptides representing HDAg residues 2 to 17, 156 to
184, 167 to 184, and 197 to 211 were synthesized in bulk and
tested for antigenic activity by a microdilution ELISA. The
results of assays with these bulk-synthesized peptides con-
firmed the validity of the pin-based hexapeptide ELISA
screening tests (Fig. 7). Maximal antigenic activity was
associated with the largest peptide, representing residues
156 to 184, which demonstrated substantial antigenic activity
with as little as 75 pg of peptide applied in solution to ELISA
plate wells (Fig. 7B). The 156 to 184 peptide contains an
internal tripeptide sequence of three glycine residues (164 to
166), suggesting that it may comprise two distinct functional
domains; thus, peptide 167-184 was synthesized to represent
the carboxy domain of this peptide. Results shown in Fig. 7B
and C suggest that domains on either side of the three glycine
residues contribute to the antigenic activity of the 156-184
peptide. Peptide 167-184 was strongly antigenic, although
less so than the 156-184 peptide. It should be noted, how-
ever, that the hexapeptide APGGGF (162 to 167) had signif-
icant antigenic activity in hexapeptide screening assays (Fig.
3A). Less antigenic activity was evident with a peptide
representing residues 197 to 211, and only limited activity
was found with peptide 2-17 (Fig. 7a and d). Although we did
not assess the efficiency with which these peptides bound to
the plastic microdilution plate, the degree of reactivity of
each of the human sera with individual peptides was propor-
tionate to the degree of binding of antibodies in pin-based
TABLE 3. Detection of anti-HD by synthetic peptide ELISA
Serum OD490 at 1:100 serum dilution (endpoint titer)
sample 2-17" 156-184 167-184 197-211
AD062 0.07 (<102) -2.95 (.106) -2.95 (105) 0.34 (102)
AF043 0.06 (<102) ::-2.95 (105) 1.29 (103) 0.28 (102)
AC036 0.33 (102) .2.95 (.106) .2.95 (2105) 2.53 (102)
AC039 0.09 (<102) -2.95 (.106) .2.95 (105) .2.95 (104)
AD099 0.09 (<102) 0.04 (<102) 0.05 (<102) 0.03 (<102)
A008 0.01 (<102) 0.02 (<102) 0.02 (<102) 0.02 (<102)
A073 0.01 (<102) 0.05 (<102) 0.03 (<102) 0.02 (<102)
hexapeptide ELISAs (Table 3). Serum AD099 did not react
with any of the four bulk-synthesized peptides, consistent
with the fact that its reactivity with hexapeptides suggested
dominant (but relatively weak) reactivity in the region 180 to
193.
DISCUSSION
Although the genomic and antigenomic RNAs of HDV
potentially encode several additional proteins (17, 19, 26,
27), HDAg is the only viral protein known to be expressed
during HDV infection in vivo. The function of this protein in
the replicative cycle of HDV is not clear. HDAg may have a
role in packaging of HDV RNA and assembly of the HDV
particle. However, the nuclear location and apparent RNA-
binding activity of HDAg suggest that it may provide addi-
tional functions necessary for the replication of viral RNA
(5). That this is so is further suggested by the recent
observation that expression of HDAg promotes the replica-
tion ofHDV RNA following transfection of cell cultures with
cloned HDV cDNA (16). While the HDAg domain involved
in its putative RNA-binding activity is unknown, it seems
likely that this function may be mediated by the highly basic
amino half of the molecule. It is of interest that the major
antigenic domains recognized by human antibodies were
found in the less hydrophilic carboxy region of the protein.
Reactivity of human sera with peptides representing residues
197 to 207 of HDAg provides strong evidence that the entire
HDV protein is expressed in vivo, as these residues lie
downstream of the amber stop codon found in some HDV
cDNA clones at residue 195 (16, 28).
The approach we utilized for mapping the epitopes of
HDAg involved the synthesis of 209 hexapeptides, overlap-
ping each other by 5 residues and spanning the entire 214
residues that most likely constitute the p276 form of HDAg.
These peptides were synthesized on polyethylene pins con-
figured in a microdilution format, a method first described by
Geysen et al. (11) that allows their direct and repeated use in
ELISA to determine antibody binding activity. This method
has previously been utilized to map epitopes of several
proteins (11-13) and, based on our results, appears to be
particularly useful when the epitopes of interest are sequen-
tial and easily detected in immunoblots of denatured antigen.
The power of this procedure rests in the ease and economy
with which many peptides can be synthesized and tested for
antigenic activity. The analysis presented in this paper
represents the results of >1,000 separate tests involving
unique antibody-peptide combinations, many of which were
repeated several times.
An obvious limitation of this epitope-mapping technique,
however, is its inability to map epitopes that are conforma-
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ute to the overall antigenicity of HDAg cannot be assessed
from the studies reported here, but this possibility must be
considered likely. The probability that HDAg has additional
conformationally defined epitopes is increased by the fact
that we have been unable to block effectively the binding of
polyclonal human antibody to woodchuck liver-derived
HDAg with excess quantities of the four peptides listed in
Table 3 (J.-G. Wang and S. M. Lemon, unpublished data).
Given the expectation that oligopeptide mapping will fail to
define conformational epitopes, it is remarkable that the
antigenic domains shown in Table 2 involve 88 (41%) of the
214 amino acids residues in the protein. This observation is
consistent with the suggestion that most if not all of the
accessible surface of a protein may be immunogenic in its
native state (2).
A second and less obvious limitation of the pin-based
oligopeptide approach to epitope mapping is related to the
purity of the peptides synthesized on pins. As these peptides
are not cleaved from the pins following their synthesis and
undergo no physical purification steps, impurities due to
unplanned side chain reactions or other irregularities in the
synthesis accumulate with the addition of residues to the
immobilized peptide. Thus, there are inherent limitations to
the length of peptides that can be usefully synthesized in this
fashion. While 6-mers are at the extreme minimum with
respect to the limits on length of peptides that would be
expected to preserve antigenic activity (12), it may be argued
that screening by ELISA against hexapeptides provided a
stringent approach capable of detecting short domains hav-
ing the greatest affinity for relevant antibodies. Whether
screening against larger peptides (8-mers or 10-mers, which
are possible by this method) would have resulted in a
significantly different picture of the epitopes of HDAg is
unknown. This would appear to be unlikely, however, given
the results of microdilution ELISAs with bulk-synthesized
oligopeptides which were 15 to 29 residues in length (Table
3). These results, when analyzed quantitatively, were en-
tirely what would have been predicted from the hexapeptide-
screening ELISAs.
Consistent with its proposed role as a nucleic acid-binding
protein, HDAg has been shown to be phosphorylated at
multiple serine residues (5). The contribution of serine
phosphorylation to the antigenicity of the molecule is un-
known and was not explored in these studies with synthetic
peptides. Lack of phosphorylation among serine residues in
the synthetic hexapeptides is unlikely to have contributed to
an inability to detect immunogenic domains, however, as the
majority of the serine residues in HDAg occur in regions that
were identified as contributing to epitopes. It is possible,
however, that other posttranslational modifications to HDAg
may affect the antigenicity of the native protein.
The data presented in Table 3 suggest the possibility that
synthetic peptides might be useful diagnostic reagents that
could be employed in new assays for anti-HD antibodies.
Recent studies with the 156-184 peptide suggest that it is
recognized by IgG antibody present in approximately 90% of
anti-HD-positive sera and that it may provide the basis for an
antibody test that is significantly more sensitive than existing
competitive immunoassays (Wang and Lemon, unpublished
data). Further studies of the immune response to this and
other HDAg peptides will be of interest in determining
whether there are differences in the fine structure of the
B-cell response to this protein in acute and chronic HDV
infections and in assessing the isotype-specific responses to
this antigen.
In addition, it is known that previous HDV infection of
HBV carrier chimpanzees results in at least partial protec-
tion against severe hepatitis following reexposure to HDV
(23). The molecular basis of this immunity is not clear.
However, inasmuch as HDAg is the only protein product
known to be expressed by the HDV genome during infection
in vivo, it is likely that this protection reflects the humoral or
cellular immune response to HDAg. It is therefore intriguing
to speculate that immunization with one or more of these
antigenic HDAg peptides might provide a means of protec-
tion of HBV carriers from HDV superinfection. Given the
existence of 200 million carriers of HBV worldwide, explo-
ration of the protective efficacy of such immunogens for
HDV would seem well worthwhile.
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